191 related articles for article (PubMed ID: 25595903)
1. CD117⁺ cells in the circulation are predictive of advanced prostate cancer.
Kerr BA; Miocinovic R; Smith AK; West XZ; Watts KE; Alzayed AW; Klink JC; Mir MC; Sturey T; Hansel DE; Heston WD; Stephenson AJ; Klein EA; Byzova TV
Oncotarget; 2015 Jan; 6(3):1889-97. PubMed ID: 25595903
[TBL] [Abstract][Full Text] [Related]
2. CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance.
Harris KS; Shi L; Foster BM; Mobley ME; Elliott PL; Song CJ; Watabe K; Langefeld CD; Kerr BA
Sci Rep; 2021 Jan; 11(1):1465. PubMed ID: 33446896
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma.
Foroozan M; Roudi R; Abolhasani M; Gheytanchi E; Mehrazma M
Pathol Res Pract; 2017 Jun; 213(6):612-618. PubMed ID: 28552539
[TBL] [Abstract][Full Text] [Related]
4. Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease.
Hoogland AM; Verhoef EI; Roobol MJ; Schröder FH; Wildhagen MF; van der Kwast TH; Jenster G; van Leenders GJ
Prostate; 2014 May; 74(5):488-96. PubMed ID: 24375374
[TBL] [Abstract][Full Text] [Related]
5. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer.
Aragon-Ching JB; Siegel RS; Frazier H; Andrawis R; Hendricks F; Phillips M; Jarrett T; Guebre-Xabiher H; Patierno S; Simmens SJ
Clin Genitourin Cancer; 2015 Oct; 13(5):e341-5. PubMed ID: 25956468
[TBL] [Abstract][Full Text] [Related]
7. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.
Shariat SF; Lamb DJ; Kattan MW; Nguyen C; Kim J; Beck J; Wheeler TM; Slawin KM
J Clin Oncol; 2002 Feb; 20(3):833-41. PubMed ID: 11821468
[TBL] [Abstract][Full Text] [Related]
8. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
9. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
[TBL] [Abstract][Full Text] [Related]
10. Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer.
Todenhöfer T; Hennenlotter J; Keller G; Neumann T; Stenzl A; Bedke J
Prostate; 2017 Sep; 77(12):1251-1258. PubMed ID: 28726251
[TBL] [Abstract][Full Text] [Related]
11. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.
Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM
Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
Szarvas T; Becker M; Vom Dorp F; Meschede J; Scherag A; Bánkfalvi A; Reis H; Schmid KW; Romics I; Rübben H; Ergün S
Int J Cancer; 2011 Mar; 128(6):1486-92. PubMed ID: 20473942
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells in prostate cancer: beyond enumeration.
Chen JF; Lu YT; Cheng S; Tseng HR; Figlin RA; Posadas EM
Clin Adv Hematol Oncol; 2017 Jan; 15(1):63-73. PubMed ID: 28212371
[TBL] [Abstract][Full Text] [Related]
15. Serum lipid profiles: novel biomarkers predicting advanced prostate cancer in patients receiving radical prostatectomy.
Zhang GM; Qin XJ; Zhang HL; Xiao WJ; Zhu Y; Gu CY; Dai B; Shi GH; Ye DW
Asian J Androl; 2015; 17(2):239-44. PubMed ID: 25475662
[TBL] [Abstract][Full Text] [Related]
16. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
Shariat SF; Shalev M; Menesses-Diaz A; Kim IY; Kattan MW; Wheeler TM; Slawin KM
J Clin Oncol; 2001 Jun; 19(11):2856-64. PubMed ID: 11387358
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen only progression of prostate cancer.
Moul JW
J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
[TBL] [Abstract][Full Text] [Related]
18. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
19. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
[TBL] [Abstract][Full Text] [Related]
20. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
